刚果荜澄窃脂素 | 13060-15-6

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物 - 呋喃类木脂素
• 中文名称: 刚果荜澄窃脂素
• 英文名称: aschantin
• 英文别名: ashantin；5-[(3S,3aR,6S,6aR)-6-(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-1,3-benzodioxole
• CAS: 13060-15-6
• 化学式: C₂₂H₂₄O₇
• 分子量: 400.428
• InChiKey: ONDWGDNAFRAXCN-VUEDXXQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  64.6
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• WGK Germany：
  3

反应信息

• 作为产物：
  描述：

  5-bromo-6-((1S,3aR,4S,6aR)-4-(3,4,5-trimethoxyphenyl)tetrahydro-1H,3H-furo[3,4-c]furan-1-yl)benzo[d][1,3]dioxole 在 tris-(dibenzylideneacetone)dipalladium(0) 、 sodium formate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以91%的产率得到刚果荜澄窃脂素
  参考文献：
  名称：

  Chromatography-free “two-pots” asymmetric total synthesis of (+)-sesamin and (+)-aschantin

  摘要：

  A gram-scale chromatography-free asymmetric total synthesis of both homo- and heterobiaryl furofuran lignans containing at least one methylenedioxy phenyl unit such as (+)-sesamin and (+)-aschantin is accomplished in "two-pots" from easily accessible enantiopure lactone involving four steps in high overall yields. Steps- and pot economy are the key advantages of the protocol. Additionally, the bromo-functionality of the intermediates is useful for late stage functionalization. (C) 2020 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2020.131483

文献信息

• PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CHRONIC OBSTRUCTIVE LUNG DISEASE CONTAINING, AS ACTIVE INGREDIENT, MAGNOLIAE FLOS EXTRACT, FRACTION, OR ACTIVE FRACTION THEREOF
  申请人：Korea Research Institute of Bioscience and Biotechnology

  公开号：EP3295947A2

  公开（公告）日：2018-03-21

  The present invention relates to a pharmaceutical composition comprising any of an extract of Magnoliae flos, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient for preventing and treating chronic obstructive pulmonary disease. It was confirmed that the extract of Magnoliae flos, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-α and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines. Therefore, the extract of Magnoliae flos, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom can be advantageously used as a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease.

  本发明涉及一种药物组合物，该药物组合物包含厚朴提取物、用有机溶剂分馏得到的馏分或活性馏分以及从中分离得到的化合物中的任意一种，作为预防和治疗慢性阻塞性肺病的活性成分。研究证实，厚朴提取物、用有机溶剂分馏得到的馏分或活性馏分，或从中分离得到的化合物，可抑制 TNF-α 诱导的 MUC5AC 的表达和人肺癌粘膜细胞（H292）的启动子活性，减少慢性阻塞性肺病小鼠模型支气管肺泡灌洗液中的炎症细胞数量，抑制活性氧的产生，减少细胞因子。因此，厚朴提取物、用有机溶剂分馏得到的馏分或活性馏分，或从中分离出的化合物可作为预防或治疗慢性阻塞性肺病的药物组合物。
• Pharmaceutical composition for preventing and treating chronic obstructive lung disease containing, as active ingredient, Magnoliae flos extract, fraction, or active fraction thereof
  申请人：KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

  公开号：US10376553B2

  公开（公告）日：2019-08-13

  A pharmaceutical composition includes any of an extract of Magnoliae flos, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient. The extract of Magnoliae flos, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-α and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines; and therefore are effective in preventing or treating chronic obstructive pulmonary disease.

  一种药物组合物包括作为活性成分的厚朴提取物、用有机溶剂分馏得到的馏分或活性馏分以及从中分离出的化合物中的任意一种。厚朴提取物、用有机溶剂分馏得到的馏分或活性馏分或从中分离得到的化合物可抑制 TNF-α 诱导的 MUC5AC 的表达和人肺癌粘膜细胞（H292）的启动子活性，减少慢性阻塞性肺病小鼠模型支气管肺泡灌洗液中炎性细胞的数量，抑制活性氧的产生，减少细胞因子；因此可有效预防或治疗慢性阻塞性肺病。
• Stereocontrolled Total Syntheses of Optically Active Furofuran Lignans
  作者：Yoshitaka Hamashima、Toshiyuki Kan、Makoto Inai、Ryo Ishikawa、Naoto Yoshida、Nana Shirakawa、Yusuke Akao、Yusuke Kawabe、Tomohiro Asakawa、Masahiro Egi

  DOI：10.1055/s-0034-1378812

  日期：——

  Plant products (+)-sesamin, (+)-sesaminol, (+)-methylpiperitol, (+)-aschantin, and (+)-5'-hydroxymethylpiperitol were synthesized in a highly stereocontrolled manner through L-proline-catalyzed bifunctional-urea-accelerated cross-aldol reaction, followed by biomimetic construction of the furofuran lignan skeleton through a quinomethide intermediate.
• COMPOSITION CONTAINING LIGNAN COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER
  申请人：KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

  公开号：US20160228402A1

  公开（公告）日：2016-08-11

  The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition. Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.
• US9820963B2
  申请人：——

  公开号：US9820963B2

  公开（公告）日：2017-11-21